Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Medicenna Therapeutics Corp T.MDNA

Alternate Symbol(s):  MDNAF

Healthcare Biotechnology
Medicenna Therapeutics Corp. is a Canada-based clinical-stage immunotherapy company. The Company's principal business activity is the development and commercialization of interleukin-2 (IL-2), interleukin-4 (IL-4) and interleukin-13 (IL-13) Superkines and Empowered Superkines for the treatment of cancer, inflammation and immune-mediated diseases. Its long-acting IL-2 Superkine, MDNA11, is an IL-2 with superior CD122 (IL-2 receptor beta) binding without CD25 (IL-2 receptor alpha) affinity, thereby preferentially stimulating cancer-killing effector T cells and NK cells. The Company’s IL-4 Empowered Superkine, bizaxofusp, has been studied in five clinical trials including a Phase IIb trial for recurrent glioblastoma (GBM). The Company’s early-stage Bifunctional SuperKine ImmunoTherapies (BiSKITs) program Targeted Metalloprotease Activated SuperKine (T-MASK) programs are designed to enhance the ability of Superkines to treat immunologically cold tumors.


TSX:MDNA - Post by User

Medicenna Therapeutics Corp > Medicenna Provides Clinical Update and Announces First Compl
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(291)
•••
Post by whytestockson Dec 05, 2024 11:00am
50 Views
Post# 36347203

Medicenna Provides Clinical Update and Announces First Compl

Medicenna Provides Clinical Update and Announces First Compl
NEWS: $MDNAF Medicenna Provides Clinical Update and Announces First Complete Responder in MDNA11 and KEYTRUDA&#xAE; (pembrolizumab) Combination Dose Escalation Arm of the ABILITY-1 Study70-year-old patient with advanced chemo-refractory anal cancer achieves complete response (CR) in 8 weeks when treated with MDNA11 in combination with Merck&#x2019;s (known as MSD outside of the US and Canada) anti-PD-1 therapy, KEYTRUDA &#xAE; (pembrolizumab) Complete regression of a...MDNAF - Medicenna Provides Clinical Update and Announces First Complete Responder in MDNA11 and KEYTRUDA&#xAE; (pembrolizumab) Combination Dose Escalation Arm of the ABILITY-1 Study

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities